Clinical Trial

Personalized DC Vaccines in Non Small Cell Lung Cancer

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Phase Ib clinical trial using autologous dendritric cell (DC) vaccine loaded with personalized peptides (PEP) given in combination with low-dose cyclophosphamide, as standard of care (SOC) therapy in patients with advanced or recurrent metastatic NSCLC.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-01-17; most recent amendment 2025-07-07.
Status change: Recruiting → Active, Not Recruiting 2025-07-07
Trial Details
NCT Number NCT05195619
Lead Sponsor Centre Hospitalier Universitaire Vaudois
Conditions Non-small Cell Lung Cancer
Enrollment 16 participants
Start Date 2022-03-22
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2025-07-10